Ionis Pharma's Phase 3 OASIS-HAE Study Of Donidalorsen In He

Ionis Pharma's Phase 3 OASIS-HAE Study Of Donidalorsen In Hereditary Angioedema Meets Main Goal

(RTTNews) - Ionis Pharmaceuticals, Inc. (IONS) Monday said Phase 3 OASIS-HAE study of donidalorsen in people with hereditary angioedema (HAE) met ...

Related Keywords

, European Medicines Agency , Ionis Pharmaceuticals Inc , Drug Administration , New Drug Application , Marketing Authorization Application , European Medicines ,